Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) — free guideline decision tool
This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) do?
Use when escalating T2DM therapy: comorbid heart failure or CKD favors an SGLT2i, ASCVD or high cardiovascular risk favors a GLP-1RA or SGLT2i, and the absence of these favors individualized dual therapy.
How is the result calculated?
Decision logic: heart failure/CKD → SGLT2i (GLP-1RA if eGFR < 30); ASCVD/high risk → GLP-1RA or SGLT2i regardless of HbA1c; otherwise individualized add-on by hypoglycemia risk, weight, and cost.
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) now
This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.